Feature | May 14, 2012

APBI as Good as Whole Breast RT in Early Stage Cancer

The MammoSite ML 1 from Hologic is one of the devices used for accelerated partial breast irradiation (APBI).

May 14, 2012 — Using a concentrated, highly targeted dose of radiation to the breast has equally as good results as irradiating the whole area, with no adverse effects on survival and a much better cosmetic outcome, Hungarian researchers have found.

Reporting the 10-year results of a randomised trial, Professor Csaba Polgár, M.D., director of the Centre for Radiotherapy, National Institute of Oncology, Budapest, told the World Congress of Brachytherapy (WCB) that he believes accelerated partial breast irradiation (APBI) could be offered to many more breast cancer patients, resulting in fewer side effects and major cost savings to healthcare systems. The WCB was held in parallel with the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31), both taking place in Barcelona between May 9-13.

The Budapest trial was the first randomised study to compare the efficacy and side effects of conventional whole breast irradiation (WBI) with APBI using multicatheter brachytherapy. This technique consists of inserting multiple plastic catheters into the tumor bed after breast conserving surgery. The catheters are inserted under local or general anaesthesia, according to the wishes of the patient. The radiation source is then loaded into them to deliver a highly concentrated dose to the precise region of the excised tumour – the region most likely to develop a local recurrence of the cancer. Using APBI means that the major part of the healthy breast tissue does not receive radiation.

“In a group of 258 women who had had breast-conserving surgery, we found that, at a median follow-up time of just over 10 years, the rate of local recurrence – the cancer coming back in the same place – was 5.9 percent in the APBI group and 5.1 percent in the group who received whole breast irradiation,” says Polgár. “There was no significant difference in overall survival, cancer-specific survival and disease-free survival between the two groups. However, the differences in cosmetic outcome were striking – 81 percent in the APBI group had good-to-excellent results as opposed to 63 percent of those who received whole breast irradiation.”

A further advantage of APBI is that treatment time can be shortened. As opposed to whole breast irradiation, where a course of treatment typically takes five weeks (five treatments per week), APBI can be carried out in four to five days. “We believe that the results of our trial will encourage more patients to choose APBI, particularly those who may now be inclined to refuse radiotherapy because of the logistical difficulties involved – having to travel long distances over a period of six weeks can be a major problem for some patients,” Polgár said.

Fewer than 10 percent of early stage breast cancer patients currently receive APBI in Europe, and in some countries it is still considered an investigational treatment. In other parts of the world, including the United States, it has been accepted into general practice for the treatment of selected low-risk patients.

“Our trial has shown that it is possible to use a faster and more focused treatment without compromising survival. It is a little like comparing a total mastectomy with a lumpectomy – we have found that we can improve cosmetic outcomes, lessen side effects and achieve greater patient satisfaction with a less invasive and more cost-effective technique. Other multi-center trials of APBI are currently underway, and we believe that these are likely to give further support to our findings,” Polgár concluded.

Christine Haie-Meder, M.D., radiation oncologist at the Institut Gustave Roussy, Villejuif, France and chairperson of the congress, said, “We know that all the patients with breast cancer do not need whole breast irradiation. Especially in elderly patients, the treatment, when limited to partial breast irradiation, can be significantly shortened. This study is important because, within the frame of a randomised trial with a 10-year followup, it shows that in selected patients, partial breast irradiation gives as good results as whole breast irradiation with the same recurrence rate, but with significantly better cosmetic results.”

Related Content

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Overlay Init